Telix Pharmaceuticals is a biotechnology business based in Australia. Telix Pharmaceuticals shares (TLX) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Telix Pharmaceuticals has a trailing 12-month revenue of around $502.5 million. If you're looking to buy shares, check out the steps below.
To buy shares listed in Australia such as Telix Pharmaceuticals , you'll need to sign up to a broker with access to the ASX. Our table can help you compare share trading platforms and choose. Then follow these steps.
Our top pick for
Best for beginner
Our top pick for
Education & learning
Our top pick for
Australian stocks
| 52-week range | $8.2 - $14.46 |
|---|---|
| 50-day moving average | $12.0208 |
| 200-day moving average | $10.7903 |
| Target price | $14.88 |
| PE ratio | 695.25 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.02 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$14.1
| 1 week (2024-04-16) | 10.76% |
|---|---|
| 1 month (2024-03-22) | 11.99% |
| 3 months (2024-01-24) | 27.95% |
| 6 months (2023-10-24) | 66.47% |
| 1 year (2023-04-24) | 38.78% |
|---|---|
| 2 years (2022-04-22) | 217.57% |
| 3 years (2021-04-23) | 261.54% |
| 5 years (2019-04-24) | 1,493.22% |
Valuing Telix Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Telix Pharmaceuticals 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Telix Pharmaceuticals 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 695x. In other words, Telix Pharmaceuticals shares trade at around 695x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Telix Pharmaceuticals 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $57.2 million (£0.0 million).
The EBITDA is a measure of a Telix Pharmaceuticals 's overall financial performance and is widely used to measure stock profitability.
| Revenue TTM | $502.5 million |
|---|---|
| Operating margin TTM | 7.23% |
| Gross profit TTM | $98.5 million |
| Return on assets TTM | 9.92% |
| Return on equity TTM | 4.55% |
| Profit margin | 1.04% |
| Book value | 0.46 |
| Market capitalisation | $4.6 billion |
TTM: trailing 12 months
We're not expecting Telix Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Telix Pharmaceuticals 's shares have ranged in value from as little as $8.2 up to $14.46. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Telix Pharmaceuticals 's is 2.35. This would suggest that Telix Pharmaceuticals 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and related medical devices for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase II clinical trials for the treatment of glioblastoma (brain cancer); TLX66, which is in Phase II clinical trials for the treatment of bone marrow conditioning and rare diseases; and TLX300 that is in Phase I clinical trial for the treatment and diagnosis of soft tissue sarcoma. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX599-CDx for treatment of prostate cancer imaging agent. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
ANZ Group Holdings Ltd. Pfd.
AUD101.63
ANZ Group Holdings Ltd. Pfd.
AUD103.35
Challenger Ltd Preferred
AUD105.11
Macquarie Bank Ltd Pref
AUD106.27
Macquarie Group Ltd Pref C
AUD102.98
Macquarie Group Preferred
AUD102.66
Macquarie Group Limited
AUD105.62
Suncorp Group Ltd Pref
AUD100.61
Westpac Banking Corp Pref
AUD102.93
Everything we know about the Tasmea Limited IPO, plus information on how to buy in.
Steps to owning and managing Blinklab shares.
Everything we know about the Maverick Minerals IPO, plus information on how to buy in.
Steps to owning and managing Far Northern Resources shares.
Commodity ETFs can be used to hedge against inflation. Here's what they do, why they should be on your watchlist and how they can help your portfolio.
Looking for the best performing stocks in Australia? We update this list weekly.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Trade ASX stocks and ETFs with a flat $2 brokerage fee and a low minimum investment of just $10.
These ETFs have the lowest fees on the market, but does that make them the best?
You've heard of CommSec but how does it stack up to the likes of IG, CMC Invest and other players in the market?